Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 3
1992 1
1993 1
1995 1
2004 2
2005 1
2007 1
2010 2
2012 1
2013 1
2016 3
2017 3
2018 1
2019 4
2020 9
2021 7
2022 5
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease.
Hampel H, Caraci F, Cuello AC, Caruso G, Nisticò R, Corbo M, Baldacci F, Toschi N, Garaci F, Chiesa PA, Verdooner SR, Akman-Anderson L, Hernández F, Ávila J, Emanuele E, Valenzuela PL, Lucía A, Watling M, Imbimbo BP, Vergallo A, Lista S. Hampel H, et al. Among authors: watling m. Front Immunol. 2020 Mar 31;11:456. doi: 10.3389/fimmu.2020.00456. eCollection 2020. Front Immunol. 2020. PMID: 32296418 Free PMC article. Review.
Time to test antibacterial therapy in Alzheimer's disease.
Panza F, Lozupone M, Solfrizzi V, Watling M, Imbimbo BP. Panza F, et al. Among authors: watling m. Brain. 2019 Oct 1;142(10):2905-2929. doi: 10.1093/brain/awz244. Brain. 2019. PMID: 31532495 Review.
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?
Vecchio FL, Bisceglia P, Imbimbo BP, Lozupone M, Latino RR, Resta E, Leone M, Solfrizzi V, Greco A, Daniele A, Watling M, Panza F, Seripa D. Vecchio FL, et al. Among authors: watling m. Ther Adv Chronic Dis. 2022 Mar 17;13:20406223221081605. doi: 10.1177/20406223221081605. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35321401 Free PMC article. Review.
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R, Krueger JG, Glatt S, Vajjah P, Mistry C, Page M, Edwards H, Garcet S, Li X, Dizier B, Maroof A, Watling M, El Baghdady A, Baeten D, Ionescu L, Shaw S. Oliver R, et al. Among authors: watling m. Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27. Br J Dermatol. 2022. PMID: 34687214 Free PMC article. Clinical Trial.
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S. Glatt S, et al. Among authors: watling mil. Ann Rheum Dis. 2018 Apr;77(4):523-532. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23. Ann Rheum Dis. 2018. PMID: 29275332 Free PMC article. Clinical Trial.
41 results